Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression
Open accessThe DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.
Abstract
Blockade of the checkpoint inhibitor programmed death 1 (PD1) has demonstrated remarkable success in the clinic for the treatment of cancer; however, a majority of tumors are resistant to anti-PD1 monotherapy. Numerous ongoing clinical combination therapy studies will likely reveal additional therapeutics that complement anti-PD1 blockade. Recent studies found that immunogenic cell death (ICD) improves T cell responses against different tumors, thus indicating that ICD may further augment antitumor immunity elicited by anti-PD1. Here, we observed antitumor activity following combinatorial therapy with anti-PD1 Ab and the cyclin-dependent kinase inhibitor dinaciclib in immunocompetent mouse tumor models. Dinaciclib induced a type I IFN gene signature within the tumor, leading us to hypothesize that dinaciclib potentiates the effects of anti-PD1 by eliciting ICD. Indeed, tumor cells treated with dinaciclib showed the hallmarks of ICD including surface calreticulin expression and release of high mobility group box 1 (HMGB1) and ATP. Mice treated with both anti-PD1 and dinaciclib showed increased T cell infiltration and DC activation within the tumor, indicating that this combination improves the overall quality of the immune response generated. These findings identify a potential mechanism for the observed benefit of combining dinaciclib and anti-PD1, in which dinaciclib induces ICD, thereby converting the tumor cell into an endogenous vaccine and boosting the effects of anti-PD1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“dinaciclib promotes immunogenic cell death (ICD) along with robust type I IFN signaling (and despite PD-L1 upregulation in this setting) in mouse models of colorectal cancer (CRC), ultimately favoring dendritic cell (DC) activation and recruitment of CD8 + T cells that can be actioned with ICIs specific for PD-1”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Hossain et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Cited by
Items 201–218 of 218
Current progress in targeting mitotic kinases in PDAC
Barlow, T. M. A., Rooman, I., & Ballet, S. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00162e
Wu, H., Wei, G., Luo, L., Li, L., Gao, Y., Tan, X., Wang, S., Chang, H., Liu, Y., Wei, Y., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26552536
Gong, Z., Jia, Q., Guo, J., Li, C., Xu, S., Jin, Z., Chu, H., Wan, Y. Y., Zhu, B., & Zhou, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26560856
Doleschel, D., Hoff, S., Koletnik, S., Rix, A., Zopf, D., Kiessling, F. M., & Lederle, W. (2021) · Figshare · doi:10.6084/m9.figshare.16614431
Doleschel, D., Hoff, S., Koletnik, S., Rix, A., Zopf, D., Kiessling, F. M., & Lederle, W. (2021) · Figshare · doi:10.6084/m9.figshare.16614434
Cui, J., Xu, H., Shi, J., Fang, K., Liu, J., Liu, F., Chen, Y., Liang, H., Zhang, Y., & Piao, H. Z. (2023) · Figshare · doi:10.6084/m9.figshare.23606849
Inhibition of Transcription by Dactinomycin Reveals a New Characteristic of Immunogenic Cell Stress
Humeau, J. (2019) · theses.fr (ABES) · doi:10.70675/e42505daza57fz459az9dc5z1ef744d25b38
Danlos, F. (2021) · theses.fr (ABES) · doi:10.70675/ff8cb58bzc391z43f8zbd32zc8c4b2cdc725
Modulation of tumor immunogenicity with AMPK activation in acute myeloid leukemia
Mondésir, J. (2021) · theses.fr (ABES) · doi:10.70675/2693bda5ze768z4bf0z857bze1eb8ccccc80
Cheng, Q., Li, S., Deng, L. W., Li, X., Hu, H., Li, J., Zhang, L., Guo, B., Zheng, C., & Zhang, J. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.06.058 · Cited by 1
Wu, Y. J., Li, J., & Li, M. M. (2026) · Research Square · doi:10.21203/rs.3.rs-9708498/v1
ICBcDrug: An online resource and tool for screening and predicting immunotherapy combination drugs
Lin, Y. Y., Sun, W., Xia, Y., Zhang, Z., Liao, Y., Shen, W., Tan, Z., Du, W., Lei, Q., & Guo, A. (2026) · Chinese Medical Journal · doi:10.1097/cm9.0000000000004160
Zhou, P., Wang, D., Zhang, H., Zhang, F., Li, Z., & Xi, H. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1882680
李, 仁., Pan, X., & Zhang, T. (2026) · Journal of Biomaterials Applications · doi:10.1177/08853282261494811
Zhang, C., Liu, Y., Chen, Y., Xu, X., Sun, Z., Tan, R., Li, Z., Zhang, H., Liu, S., Xiao, J., et al. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218914
BindingDB Entry 50018115: CDK9 inhibitors in cancer research.
BindingDB (2024) · UC San Diego · doi:10.7270/q24b35h7
BindingDB (2023) · UC San Diego · doi:10.7270/q28k7f2w
Metadata
- Authors
- Hossain, D. M. S., Javaid, S., Cai, M., Zhang, C., Sawant, A., Hinton, M., Sathe, M., Grein, J., Blumenschein, W., Pinheiro, E. M., & Chackerian, A.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Chackerian, Alissa
- Venue
- Journal of Clinical Investigation
- Published
- 2018-01-16
- Volume
- 128
- Issue
- 2
- Pages
- 644-654
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC5785250
- OpenAlex
- W2783507731
- Cited by
- 216
- References
- 88
- Citations by year
- 2026: 11 · 2025: 25 · 2024: 37 · 2023: 45 · 2022: 29 · 2021: 22 · 2020: 32 · 2019: 11 · 2018: 4
- FWCI
- 6.48
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- dinaciclib, immunogenic cell death, anti-PD-1 therapy, combination cancer immunotherapy, cyclin-dependent kinase inhibitors, type I interferon signature, calreticulin, HMGB1, ATP release, T cell infiltration, tumor immunogenicity, cancer vaccines
- MeSH terms
- Adenocarcinoma, Adenosine Triphosphate, Animals, Antibodies, Monoclonal, Cyclic N-Oxides, Dendritic Cells, Drug Synergism, Female, Immune System, Immunotherapy, Indolizines, Mice, Inbred BALB C, Mice, Inbred C57BL, Neoplasm Transplantation, Phagocytosis, Pyridinium Compounds, Cytokines, Cell Death, Apoptosis, Mice, Knockout, CD8-Positive T-Lymphocytes, Bridged Bicyclo Compounds, Heterocyclic, HMGB1 Protein, Cell Line, Tumor, Protein Kinase Inhibitors, Mice, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.